Int.J.Curr.Res.Aca.Rev.2026; 14(7): 144-150

EXCELLENT PUBLISHERS

International Journal of Current Research and Academic Review

ISSN: 2347-3215 (Online) Volume 14 Number 7 (July-2026)

Journal homepage: http://www.ijcrar.com

doi: https://doi.org/10.20546/ijcrar.2026.1407.013

Liver Cirrhosis and Abscess Disease Diagnosis, Prediction, and Detection Using Machine Learning Frameworks and Models

Rajani Kumari* **and Daya Shankar Singh**

Madan Mohan Malaviya University of Technology Gorakhpur-273010 India

**Corresponding author*

Abstract

Liver cirrhosis and hepatic abscess are major causes of global morbidity and mortality, posing significant challenges in early diagnosis and clinical management due to their heterogeneous presentation and progressive nature. Conventional diagnostic approaches, including biochemical investigations, imaging modalities, and histopathological examination, are effective but are often limited by invasiveness, inter-observer variability, delayed detection, and reduced diagnostic accuracy during the early stages of disease. Recent advances in artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), have transformed the landscape of hepatology by enabling automated, accurate, and non-invasive diagnosis of liver diseases. This review comprehensively examines the epidemiology, pathophysiology, and conventional diagnostic strategies for liver cirrhosis and hepatic abscess while highlighting the emerging role of ML-based predictive models in improving disease detection and clinical decision-making. The review discusses widely used supervised learning algorithms, including Logistic Regression, Support Vector Machine, Random Forest, Decision Tree, Extreme Gradient Boosting (XGBoost), Artificial Neural Networks, and ensemble learning techniques, alongside deep learning architectures such as Convolutional Neural Networks for liver image analysis. Furthermore, the importance of medical imaging, radiomics, data preprocessing, feature selection, model optimization, performance evaluation, explainable artificial intelligence (XAI), and external clinical validation is critically evaluated. Current challenges, including limited multicenter datasets, model interpretability, algorithmic bias, ethical concerns, and regulatory issues, are also discussed. The review concludes that integrating machine learning with multimodal clinical, laboratory, and imaging data has the potential to significantly enhance early diagnosis, prognostic assessment, and personalized management of hepatic diseases. Future research should prioritize explainable, clinically validated, and ethically governed AI frameworks to facilitate their safe translation into routine hepatology practice and precision medicine.

Article Info

Received: 20 May 2026
Accepted: 28 June 2026
Available Online:20 July 2026

Keywords

Liver Cirrhosis, Hepatic Abscess, Machine Learning, Deep Learning, Artificial Intelligence in Hepatology

Overview of Liver Cirrhosis and Hepatic Abscess: Epidemiology, Etiology, and Clinical Significance

Liver cirrhosis and hepatic abscess are major contributors to global liver-related morbidity and mortality, imposing a substantial burden on healthcare systems worldwide. Liver cirrhosis represents the final stage of chronic liver disease and is characterized by progressive hepatic fibrosis, regenerative nodule formation, distortion of the normal hepatic architecture, and irreversible loss of liver function. The principal etiological factors include chronic viral hepatitis B and C

infections, excessive alcohol consumption, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, inherited metabolic disorders, and cholestatic liver diseases (Asrani *et al.,* 2019; European Association for the Study of the Liver [EASL], 2021). The global prevalence of cirrhosis continues to increase, largely due to the rising incidence of metabolic syndrome, obesity, and type 2 diabetes mellitus, making it one of the leading causes of liver-related deaths worldwide (GBD 2021 Cirrhosis Collaborators, 2024).

Hepatic abscess is a localized collection of purulent material within the liver parenchyma resulting from bacterial, parasitic, or fungal infections. Pyogenic liver abscess (PLA) is the most prevalent form, predominantly caused by Gram-negative bacteria such as *Klebsiella pneumoniae* and *Escherichia coli*, whereas amoebic liver abscess results from infection with *Entamoeba histolytica*, particularly in tropical and developing countries (Kaplan *et al.,* 2022). Predisposing factors include diabetes mellitus, biliary tract disease, abdominal infections, malignancies, and immunosuppressive conditions. Despite advances in antimicrobial therapy and minimally invasive drainage techniques, delayed diagnosis may result in septic shock, liver failure, and increased mortality.

The clinical manifestations of liver cirrhosis and hepatic abscess often overlap, including fever, abdominal pain, hepatomegaly, jaundice, weight loss, fatigue, and abnormal liver function tests. Early diagnosis remains challenging because many patients remain asymptomatic during the initial stages or present with nonspecific symptoms. Consequently, timely diagnosis through laboratory investigations, advanced imaging modalities, and computational diagnostic approaches has become increasingly important. Recent advances in artificial intelligence (AI) and machine learning (ML) have shown considerable promise in improving the early detection, classification, and prognostic prediction of liver diseases by integrating multidimensional clinical, biochemical, and imaging datasets (Esteva *et al.,* 2019; Topol, 2019). These technologies have the potential to enhance diagnostic precision, facilitate personalized clinical decision-making, and improve patient outcomes.

Pathophysiology and Disease Progression of Liver Cirrhosis and Hepatic Abscess

Liver cirrhosis is a progressive and irreversible pathological condition characterized by chronic hepatic injury, excessive extracellular matrix deposition, fibrosis, and regenerative nodule formation, ultimately leading to distortion of normal hepatic architecture and liver dysfunction (Asrani *et al.,* 2019). The disease develops following repeated cycles of hepatocyte injury and regeneration caused by chronic viral hepatitis, excessive alcohol consumption, metabolic dysfunction-associated steatotic liver disease (MASLD), autoimmune hepatitis, and inherited metabolic disorders.

Activation of hepatic stellate cells (HSCs) plays a pivotal role in fibrogenesis. Upon liver injury, quiescent HSCs transform into activated myofibroblast-like cells that synthesize collagen types I and III, resulting in progressive fibrosis and portal hypertension (Bataller & Brenner, 2005). Persistent inflammation further stimulates the release of transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), and pro-inflammatory cytokines, accelerating hepatic remodeling and cirrhosis progression.

The clinical progression of cirrhosis involves a transition from compensated disease, where patients remain asymptomatic, to decompensated cirrhosis characterized by ascites, variceal hemorrhage, hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatorenal syndrome. Chronic oxidative stress, mitochondrial dysfunction, immune dysregulation, and endothelial injury further contribute to disease progression and increase the risk of hepatocellular carcinoma (Pinzani *et al.,* 2018).

Hepatic abscess, in contrast, represents an acute infectious process resulting from microbial invasion of hepatic tissue through the biliary tract, portal vein, hepatic artery, or direct extension from adjacent infections. Pyogenic liver abscesses are predominantly caused by *Klebsiella pneumoniae*, *Escherichia coli*, *Streptococcus* spp., and anaerobic bacteria, whereas amoebic liver abscesses are caused by *Entamoeba histolytica* (Kaplan *et al.,* 2022).

Microbial proliferation induces neutrophilic infiltration, hepatocyte necrosis, liquefactive tissue destruction, and abscess cavity formation. If untreated, infection may spread systemically, resulting in septicemia, multiple organ dysfunction syndrome (MODS), and death. Understanding these molecular and cellular mechanisms is essential for developing early diagnostic biomarkers and machine learning-based predictive models capable of identifying disease progression before irreversible hepatic damage occurs.

Conventional Diagnostic Approaches for Liver Cirrhosis and Hepatic Abscess

Early diagnosis of liver cirrhosis and hepatic abscess is essential for reducing disease-related complications and improving patient survival. Conventional diagnostic approaches integrate clinical evaluation, laboratory investigations, imaging modalities, microbiological examinations, and histopathological analysis to establish an accurate diagnosis. Patients with liver cirrhosis commonly present with fatigue, jaundice, ascites, hepatosplenomegaly, peripheral edema, and portal hypertension, whereas hepatic abscess typically manifests with fever, right upper quadrant pain, chills, anorexia, and hepatomegaly (European Association for the Study of the Liver [EASL], 2021).

Laboratory investigations include liver function tests (LFTs), complete blood count (CBC), coagulation profile, inflammatory markers, and microbiological cultures. Elevated serum bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and prolonged prothrombin time are common indicators of hepatic dysfunction. In hepatic abscess, leukocytosis, elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and positive blood cultures support the diagnosis (Marrero *et al.,* 2020).

Medical imaging remains indispensable in liver disease diagnosis. Ultrasonography is widely used as the first-line imaging modality due to its accessibility, cost-effectiveness, and ability to detect hepatic fibrosis, portal hypertension, ascites, and abscess cavities. Contrast-enhanced computed tomography (CT) provides excellent anatomical detail and is considered the gold standard for identifying hepatic abscesses, while magnetic resonance imaging (MRI) offers superior soft tissue characterization and facilitates early detection of focal liver lesions (Rockey *et al.,* 2021). Transient elastography (FibroScan®) has emerged as a reliable non-invasive technique for quantifying liver stiffness and staging hepatic fibrosis, thereby reducing the need for invasive liver biopsy.

Although liver biopsy remains the definitive standard for diagnosing fibrosis and cirrhosis, its invasive nature, sampling variability, and potential complications limit routine application. Consequently, integration of conventional diagnostic methods with artificial intelligence and machine learning algorithms is increasingly being explored to enhance diagnostic accuracy, reduce observer variability, and facilitate early disease prediction.

Role of Clinical, Biochemical, and Hematological Parameters in Disease Diagnosis

Clinical, biochemical, and hematological parameters constitute the foundation for diagnosing liver cirrhosis and hepatic abscess and are increasingly utilized as predictive variables in machine learning-based diagnostic systems. Comprehensive evaluation of these biomarkers provides valuable insights into hepatic function, inflammatory status, disease severity, and prognosis.

Clinical manifestations of liver cirrhosis include jaundice, ascites, hepatomegaly, splenomegaly, peripheral edema, hepatic encephalopathy, muscle wasting, and esophageal varices, whereas patients with hepatic abscess frequently present with fever, right upper abdominal pain, chills, nausea, anorexia, and hepatomegaly. These clinical findings guide initial diagnostic evaluation but often require laboratory confirmation due to their nonspecific nature (EASL, 2021).

Biochemical investigations primarily assess hepatocellular injury and liver synthetic function. Elevated serum AST, ALT, ALP, GGT, total bilirubin, and direct bilirubin indicate hepatic inflammation or biliary obstruction, while reduced serum albumin and prolonged prothrombin time reflect impaired hepatic synthetic capacity. Renal biomarkers such as serum creatinine and blood urea nitrogen (BUN) are important for detecting hepatorenal syndrome in advanced cirrhosis. Inflammatory biomarkers including CRP, procalcitonin, ferritin, and lactate dehydrogenase (LDH) are valuable indicators of infection and systemic inflammation, particularly in hepatic abscess (Reuben *et al.,* 2023).

Hematological parameters including hemoglobin concentration, total leukocyte count, neutrophil-to-lymphocyte ratio (NLR), platelet count, mean platelet volume (MPV), and international normalized ratio (INR) provide additional diagnostic and prognostic information. Thrombocytopenia is an early marker of portal hypertension, whereas leukocytosis and neutrophilia strongly suggest bacterial infection. Recent machine learning studies have demonstrated that integrating routine clinical, biochemical, hematological, and radiological variables substantially improves disease classification, prognostic prediction, and individualized

risk assessment. Feature selection techniques and ensemble learning algorithms have further enhanced predictive performance, highlighting the potential of data-driven precision medicine for early diagnosis and management of hepatic diseases (Topol, 2019; Krittanawong *et al.,* 2021).

Medical Imaging Techniques for Detection and Assessment of Hepatic Diseases

Medical imaging has become indispensable for the diagnosis, staging, and monitoring of liver cirrhosis and hepatic abscesses. Conventional ultrasonography (USG) remains the first-line imaging modality because it is non-invasive, inexpensive, and widely available. It facilitates the detection of hepatic parenchymal abnormalities, portal hypertension, splenomegaly, ascites, and focal liver lesions. However, its diagnostic accuracy is highly operator-dependent and limited in obese patients. Computed tomography (CT) provides superior anatomical detail and is considered the gold standard for identifying hepatic abscesses, enabling accurate visualization of lesion size, location, septations, and surrounding tissue involvement. Magnetic resonance imaging (MRI), particularly diffusion-weighted imaging (DWI) and magnetic resonance elastography (MRE), offers excellent soft-tissue contrast and high sensitivity for detecting early hepatic fibrosis and differentiating benign from malignant lesions. Elastography techniques, including transient elastography (FibroScan) and shear-wave elastography, have emerged as valuable non-invasive alternatives to liver biopsy for fibrosis staging. Recent developments in radiomics and quantitative imaging allow extraction of high-dimensional imaging features that can be integrated with machine learning algorithms for automated disease classification and prognosis. These advanced imaging technologies provide rich datasets that significantly improve diagnostic precision and facilitate personalized clinical decision-making in hepatology.

Machine Learning in Hepatology: Concepts, Applications, and Clinical Potential

Machine learning (ML), a branch of artificial intelligence, enables computers to learn complex patterns from clinical data without explicit programming. In hepatology, ML has emerged as a transformative technology for disease diagnosis, prognosis, treatment response prediction, and survival analysis. Supervised learning algorithms utilize labeled datasets to predict disease outcomes, whereas unsupervised learning identifies hidden structures and patient subgroups. Reinforcement learning is increasingly explored for personalized therapeutic strategies. ML integrates multidimensional clinical data, including demographic information, laboratory investigations, electronic health records, genomic profiles, histopathology, and radiological imaging. These algorithms have demonstrated excellent performance in predicting liver fibrosis, cirrhosis progression, portal hypertension, hepatocellular carcinoma, and hepatic infections. The integration of ML with radiomics has significantly enhanced automated lesion detection and image interpretation while reducing observer variability. Furthermore, predictive analytics can assist clinicians in early risk stratification, intensive care monitoring, and individualized treatment planning. Despite these advances, clinical implementation requires robust external validation, standardized datasets, transparency, and regulatory approval. Explainable machine learning models are increasingly emphasized to improve clinician confidence and facilitate integration into routine healthcare. As computational resources continue to expand, machine learning is expected to become an integral component of precision hepatology and evidence-based clinical decision-making.

Machine Learning Algorithms for Liver Cirrhosis Prediction and Classification

Machine learning algorithms have substantially improved the prediction and classification of liver cirrhosis by analyzing complex clinical and laboratory datasets. Logistic regression remains widely used because of its interpretability and suitability for binary classification. Decision trees and random forests effectively capture nonlinear relationships and variable interactions while providing robust predictive performance with reduced overfitting. Support Vector Machines (SVMs) have demonstrated excellent accuracy in classifying cirrhosis using biochemical markers and imaging-derived features, particularly in high-dimensional datasets. Gradient boosting algorithms such as XGBoost and LightGBM have gained popularity due to their superior predictive capabilities and computational efficiency. Artificial neural networks (ANNs) model intricate nonlinear associations and have shown promising performance in predicting fibrosis progression and clinical outcomes. Ensemble learning methods combine predictions from multiple algorithms to improve diagnostic stability and reduce classification errors. These models utilize diverse input variables, including liver enzymes, platelet count, bilirubin,

albumin, coagulation indices, fibrosis biomarkers, and imaging features. Comparative studies consistently report that ensemble-based algorithms outperform conventional statistical models in sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). Nevertheless, multicenter validation and standardized reporting remain essential before widespread clinical implementation.

Machine Learning-Based Detection and Diagnosis of Hepatic Abscess

Machine learning has recently been applied to improve the detection and diagnosis of hepatic abscesses by integrating clinical parameters with advanced imaging analysis. Hepatic abscesses often present with nonspecific symptoms, making early diagnosis challenging using conventional methods alone. Machine learning algorithms analyze radiological characteristics extracted from CT, MRI, and ultrasound images together with laboratory biomarkers such as leukocyte count, C-reactive protein, procalcitonin, liver enzymes, and blood culture results. Deep feature extraction combined with radiomics enables differentiation between pyogenic abscesses, amoebic abscesses, cystic lesions, and malignant hepatic tumors. Random forest, support vector machine, convolutional neural networks, and ensemble classifiers have demonstrated high diagnostic accuracy in lesion segmentation and classification. Automated detection systems reduce inter-observer variability and improve diagnostic consistency, particularly in emergency settings where rapid clinical decisions are required. Integration of machine learning into hospital information systems facilitates early risk prediction, individualized antimicrobial selection, and treatment monitoring. Although current studies report encouraging results, the availability of large, annotated multicenter imaging datasets remains limited. Future research should focus on prospective validation, external testing, multimodal data integration, and explainable artificial intelligence to enhance clinical acceptance and regulatory implementation.

Deep Learning and Convolutional Neural Networks for Liver Imaging Analysis

Deep learning, particularly Convolutional Neural Networks (CNNs), has revolutionized automated liver image analysis by enabling hierarchical feature extraction directly from raw medical images. CNN architectures such as ResNet, DenseNet, U-Net, EfficientNet, and VGGNet have demonstrated outstanding performance in liver segmentation, fibrosis staging, lesion detection, tumor classification, and hepatic abscess identification. Unlike traditional machine learning methods requiring handcrafted features, CNNs automatically learn discriminative image characteristics during training. Transfer learning has become increasingly valuable when large annotated medical datasets are unavailable, allowing pretrained models to achieve excellent performance with limited data. Three-dimensional CNNs further enhance volumetric analysis of CT and MRI scans by preserving spatial information across image slices. Recent advances include hybrid CNN-transformer models that capture both local and global image features, improving diagnostic accuracy. Deep learning also supports automated quantification of liver volume, fibrosis severity, portal vein abnormalities, and treatment response assessment. Despite remarkable performance, challenges remain regarding model interpretability, computational cost, dataset imbalance, and external validation. Explainable deep learning methods such as Gradient-weighted Class Activation Mapping (Grad-CAM) improve transparency by highlighting image regions influencing predictions, thereby increasing clinician trust and facilitating clinical adoption.

Data Preprocessing, Feature Selection, and Model Optimization for Hepatic Disease Prediction

Data preprocessing is a critical step in developing robust machine learning models for hepatic disease prediction. Clinical datasets often contain missing values, noise, outliers, and class imbalance, which may adversely affect model performance. Standard preprocessing techniques include normalization, standardization, imputation, duplicate removal, and categorical encoding. Handling imbalanced datasets using Synthetic Minority Oversampling Technique (SMOTE), adaptive synthetic sampling, or cost-sensitive learning improves classifier reliability. Feature selection reduces data dimensionality and eliminates redundant variables while enhancing computational efficiency and model interpretability. Common approaches include Recursive Feature Elimination (RFE), Least Absolute Shrinkage and Selection Operator (LASSO), Principal Component Analysis (PCA), Information Gain, and Random Forest feature importance. Hyperparameter optimization using Grid Search, Random Search, Bayesian Optimization, and Genetic Algorithms further improves predictive accuracy. Cross-validation techniques such as k-fold validation ensure model generalizability and reduce overfitting. Integration of preprocessing, feature

engineering, and optimization significantly enhances the performance of predictive models for liver cirrhosis and hepatic abscess diagnosis. Careful data preparation remains fundamental for developing reliable clinical decision-support systems capable of accurate disease prediction across diverse patient populations.

Performance Evaluation, Explainable Artificial Intelligence, and Clinical Validation of Machine Learning Models

Evaluation of machine learning models requires rigorous statistical assessment to ensure reliability and clinical applicability. Performance metrics include accuracy, sensitivity, specificity, precision, recall, F1-score, receiver operating characteristic (ROC) curves, area under the curve (AUC), Matthews correlation coefficient, and calibration analysis. External validation using independent multicenter datasets is essential for assessing model generalizability beyond the training population. Explainable Artificial Intelligence (XAI) addresses the "black-box" nature of complex algorithms by providing transparent explanations for model predictions. Methods such as SHapley Additive exPlanations (SHAP), Local Interpretable Model-Agnostic Explanations (LIME), and Grad-CAM identify influential clinical variables and imaging features contributing to diagnostic decisions. Explainability enhances clinician confidence, supports regulatory approval, and facilitates ethical implementation in healthcare. Prospective clinical trials comparing AI-assisted diagnosis with expert clinicians are increasingly recognized as the gold standard for validation. Integration of explainable models with electronic health records and decision-support systems has the potential to improve diagnostic consistency, reduce medical errors, and promote personalized patient management in hepatology.

Challenges, Limitations, Ethical Considerations, and Future Perspectives of AI-Based Liver Disease Diagnosis

Despite remarkable advances, several challenges limit the widespread adoption of artificial intelligence in liver disease diagnosis. Most available datasets originate from single institutions, leading to limited generalizability and increased risk of algorithmic bias. Variability in imaging protocols, laboratory methods, and patient demographics further complicates model transferability. Limited availability of annotated datasets and inconsistent reporting standards hinder reproducibility across studies. Ethical concerns include patient privacy, informed consent, algorithmic fairness, transparency, and accountability for AI-assisted clinical decisions. Regulatory agencies require rigorous evidence demonstrating safety, effectiveness, and clinical benefit before approval of AI-based diagnostic systems. Explainable AI, federated learning, privacy-preserving machine learning, and multimodal data integration represent promising future directions. Collaborative international databases and standardized reporting guidelines are essential for developing robust, clinically applicable algorithms. Future research should emphasize prospective multicenter validation, integration of genomics and multi-omics data, real-time clinical decision support, and continuous model monitoring after deployment. With appropriate validation, regulatory oversight, and ethical governance, artificial intelligence has the potential to substantially improve early diagnosis, prognostic assessment, personalized treatment planning, and healthcare delivery for patients with liver cirrhosis and hepatic abscesses.

References

Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. *Journal of Hepatology, 70*(1), 151–171. https://doi.org/10.1016/j.jhep.2018.09.014

Bataller, R., & Brenner, D. A. (2005). Liver fibrosis. *Journal of Clinical Investigation, 115*(2), 209–218.

Bi, W. L., Hosny, A., Schabath, M. B., *et al.,* (2019). Artificial intelligence in cancer imaging: Clinical challenges and applications. *CA: A Cancer Journal for Clinicians, 69*(2), 127–157.

Chawla, N. V., Bowyer, K. W., Hall, L. O., & Kegelmeyer, W. P. (2002). SMOTE: Synthetic minority over-sampling technique. *Journal of Artificial Intelligence Research, 16*, 321–357.

Chen, T., & Guestrin, C. (2016). XGBoost: A scalable tree boosting system. *Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, 785–794.

Doshi-Velez, F., & Kim, B. (2017). Towards a rigorous science of interpretable machine learning. *arXiv*. https://arxiv.org/abs/1702.08608

Esteva, A., Robicquet, A., Ramsundar, B., *et al.,* (2019). A guide to deep learning in healthcare. *Nature Medicine, 25*(1), 24–29. https://doi.org/10.1038/s41591-018-0316-z

European Association for the Study of the Liver (EASL). (2021). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. *Journal of Hepatology, 75*(3), 659–689. https://doi.org/10.1016/j.jhep.2021.05.025

GBD 2021 Cirrhosis Collaborators. (2024). Global burden of cirrhosis and chronic liver diseases, 1990–2021. *The Lancet Gastroenterology & Hepatology.*

Kaplan, G. G., Gregson, D. B., & Laupland, K. B. (2022). Epidemiology and clinical characteristics of pyogenic liver abscess. *Clinical Gastroenterology and Hepatology.*

Krittanawong, C., Johnson, K. W., Rosenson, R. S., *et al.,* (2021). Deep learning for cardiovascular medicine: A practical primer. *European Heart Journal*, 42(21), 2058–2073.

Kuhn, M., & Johnson, K. (2019). *Feature engineering and selection: A practical approach for predictive models*. CRC Press.

Lambin, P., Leijenaar, R. T. H., Deist, T. M., *et al.,* (2017). Radiomics: The bridge between medical imaging and personalized medicine. *Nature Reviews Clinical Oncology, 14*(12), 749–762.

Litjens, G., Kooi, T., Bejnordi, B. E., *et al.,* (2017). A survey on deep learning in medical image analysis. *Medical Image Analysis, 42*, 60–88.

Lundberg, S. M., & Lee, S. I. (2017). A unified approach to interpreting model predictions. *Advances in Neural Information Processing Systems, 30*, 4765–4774.

Lundervold, A. S., & Lundervold, A. (2019). An overview of deep learning in medical imaging focusing on MRI. *Zeitschrift für Medizinische Physik, 29*(2), 102–127.

Marrero, J. A., Kulik, L. M., Sirlin, C. B., *et al.,* (2020). Diagnosis, staging, and management of hepatocellular carcinoma. *Hepatology, 71*(2), 723–750.

Pinzani, M., Rosselli, M., & Zuckermann, M. (2018). Liver cirrhosis. *Best Practice & Research Clinical Gastroenterology, 32–33*, 1–13.

Reuben, A., Lai, M., & Garcia-Tsao, G. (2023). Clinical assessment and laboratory evaluation of chronic liver disease. *Hepatology.*

Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C., & Smith, A. D. (2021). Liver biopsy. *Hepatology, 74*(1), 101–120.

Tang, A., Cloutier, G., Szeverenyi, N., & Sirlin, C. B. (2015). Ultrasound elastography and MR elastography for assessing liver fibrosis. *Advances in Chronic Kidney Disease, 22*(5), 420–427.

Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine, 25*(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

World Health Organization. (2021). *Ethics and governance of artificial intelligence for health*. World Health Organization.

How to cite this article:

Pavan Goyal. 2026. Screening and Therapeutic Management of Chronic Hepatitis in a German Shepherd. *Int.J.Curr.Res.Aca.Rev.* 14(76), 144-150. doi: https://doi.org/10.20546/ijcrar.2026.1407.013